I’ve lived with type 1 diabetes for much of my life. I know what it feels like to leave an appointment with a new plan, good intentions, and a long stretch of time before…
As the healthcare landscape rapidly evolves, challenges related to medication access and affordability come to the forefront. Direct-to-consumer models reduce reliance on traditional intermediaries, such as in-person clinical visits, retail pharmacies, and…
Cancer care is complex. For patients prescribed oral oncolytics, managing side effects, staying on schedule, and coordinating care can be overwhelming. These challenges often lead to missed doses, therapy interruptions,…
This article was published in MedCity News on November 18, 2024. The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for…
This poster highlights the impact of an HSSP model on accessing Patient Assistance Program (PAP) funding for oral oncolytic drugs. Government-insured patients received PAP support more often with brand medications…
This research poster explores how the implementation of a pharmacy liaison-managed diabetes care model is associated with positive patients outcomes, including high PDC, HbA1c reductions, time to therapy initiation, and…
This white paper describes the impact of health system specialty pharmacy utilizing an integrated care model on clinical outcomes and total cost of care.
This poster examines how the HSSP care model’s impact on HIV, cardiovascular, MS, inflammatory, and transplant patients, showing reduced pharmacy expenses with a slight non-significant increase in total medical expenses.